SCHEMBL22233136

SCHEMBL22233136

Cc1cc(-n2ccc(NC(=O)N3CCN(C(=O)CC(C)(C)N)CC3)nc2=O)ccc1CN1CCC(N)CC1

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TRPV1 Q8NER1 1/20 0.34
DPP4 P27487 1/20 0.33
FAAH O00519 2/20 0.32
CNR2 P34972 1/20 0.31
EPHX2 P34913 1/20 0.30
ATM Q13315 1/20 0.30
GRIN2B Q13224 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25205737 0.99 GSK3B (0.34) GSK3BDYRK1AMEN1KMT2ATRPV1
SCHEMBL22233796 0.91 GSK3B (0.35) GSK3BDYRK1AMEN1KMT2ATRPV1
SCHEMBL22254392 0.90 FAAH (0.36) GSK3BDYRK1ATRPV1FAAHEPHX2
Hydrochloric Acid SCHEMBL30398715 0.90 GSK3B (0.34) GSK3BDYRK1AMEN1KMT2ATRPV1
Hydrochloric Acid SCHEMBL22233632 0.90 GSK3B (0.34) GSK3BDYRK1AMEN1KMT2ATRPV1
Hydrochloric Acid SCHEMBL22233846 0.90 FAAH (0.36) GSK3BDYRK1ATRPV1FAAHEPHX2
Hydrochloric Acid SCHEMBL30401077 0.90 FAAH (0.36) GSK3BDYRK1ATRPV1FAAHEPHX2
SCHEMBL25558707 0.89 MEN1 (0.36) GSK3BDYRK1AMEN1KMT2ATRPV1
SCHEMBL22255232 0.89 GSK3B (0.34) GSK3BDYRK1AMEN1KMT2ATRPV1
SCHEMBL25531588 0.89 GSK3B (0.34) GSK3BDYRK1AMEN1KMT2ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
EP-3911644-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2021-11-24 EP disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 WO disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 GSK3B 1762/4885DYRK1A 3645/4885MEN1 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.